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Background: Cases with subcutaneous metastasis of differentiated hepatocellular carcinoma to the abdominal wall
without prior seeding as a consequence of local interventions with a negative or normal alpha-fetoprotein level in
the serum are extremely rare.
Case report: This is the first report of a case with AFP-negative, differentiated hepatocellular carcinoma metastasis
to the abdominal wall within a pre-existing subcutaneous lipoma since childhood after antiandrogen therapy with
leuprorelin and buserelin acetate for prostate cancer without seeding.
Methods: Clinical features including histology, immunohistochemistry, clinical course and surgical approach are
presented.
Results: Histological examination revealed a hepatocellular carcinoma with a trabecular and pseudoglandular growth
pattern with moderately atypical hepatocytes with multifocal bile formation within a lipoma. The postoperative course
of abdominal wall reconstruction with a monocryl-prolene mesh and a local flap after potentially curative resection was
uncomplicated.
Discussion and conclusion: It may be that previous antiandrogen treatment for prostate carcinoma contributed to
the fact that our patient developed alpha-fetoprotein-negative and androgen receptor-negative subcutaneous
abdominal wall metastasis within a pre-existing lipoma since childhood.
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Hepatocellular carcinoma (HCC) remains one of the
most common malignant diseases and the incidence is
increasing worldwide [1-5]. Today, a multidisciplinary
approach including surgical, chemotherapeutic and inter-
ventional therapeutic modalities is regarded as a pre-
requisite to enable optimal results. Distant metastases
are common, the most frequent sites include the lungs,
bones, lymph nodes and adrenal glands but extrahepatic* Correspondence: schrem.harald@mh-hannover.de
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reproduction in any medium, provided the ormetastasis to the abdominal wall is comparatively very
rare [6-10].
Cases with subcutaneous differentiated metastasis of
hepatocellular carcinoma with a negative or normal
alpha-fetoprotein (AFP) level in the serum are extremely
rare (see Table 1) [11-36].
Most cases with metastasis to the abdominal wall are
described after percutaneous interventions including fine
needle aspiration biopsy (FNAB), cytology, radiofre-
quency ablation or percutaneous ethanol injection (PEI).
In the current literature during the last 10 years, only few
cases have been reported with abdominal wall metastasisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Non-iatrogenic skin metastasis from hepatocellular carcinoma described in the literature the last 10 years.
Reference N Sex Age Localisation Seeding AFP ng/ml Appearance Hepatitis
Jegou et al. (2004) [11] 1 M 55 left frontal no n.a. painless nodule n.a.
De Agustin et al. (2007) [12] 1 F 65 face no n.a. n.a. n.a.
Hsieh et al. (2007) [13] 1 M 46 left skull no 71 ng/ml soft mass B
Royer et al. (2008) [14] 1 M 74 nose no n.a. pearly purple nodule n.a.
Magana and Gomez et al. (2009) [15] 1 M 41 right cheek no n.a red papule C
Lazaro et al. (2009) [16] 1 M 61 nasal lesion no n.a. excoriated palpule n.a.
Fukushima et al. (2010) [17] 1 M 58 left skull no n.a n.a n.a
Lee et al. (2010) [18] 1 M 49 tip of nose no n.a. dark spot C
Isa et al. (2011) [19] 1 M 81 left nasal alae no normal multilobulated mass negative
Ackerman et al. (2001) [20] 1 M 52 left scapula no 10000 ng/ml hemangio-sarcoma B,C
Braune et al. (2001) [21] 1 M 76 right chest yes n.a. subcutaneous tumor n.a.
Al-Mashat FM (2004) [22] 1 M 60 chest wall n.a. n.a. n.a. n.a.
Amador et al. (2007) [23] 1 M 80 shoulder no n.a. abscess-like B
Terada et al. (2010) [24] 1 M 86 right chest no n.a cutaneous mass C
Suzuki et al. (2003) [25] 1 M 66 abdomen n.a. n.a. subcutaneous nodule C
Lee et al. (2004) [26] 1 M 68 right upper abdomen yes normal red nodule B
Hyun et al. (2006) [27] 1 M 56 left abdomen no 308 ng/ml n.a. B
Nggada et al. (2006) [28] 1 M 53 chest, back abdomen, no negative nodules B
Martinez Ramos et al. (2007) [29] 1 W 70 subxyphoid region yes 324000 ng/ml violaceous cutaneous mass C
Rowe et al. (2007) [30] 1 W 72 abdominal wall yes n.a. nodule no
Özdil et al. (2009) [31] 1 M 76 right abdomen yes 1860 ng/ml subcutaneous tumor B
Chen et al. (2011) [32] 1 F 69 abdominal wall yes 275-1217 ng/ml n.a C
Fang et al. (2001) [33] 1 M 49 back, hands, feet no n.a. reddish-blue papules n.a.
Kanitakis et al. (2003) [34] 1 F 50 right arm no increased n.a. n.a.
Nagaoka et al. (2004) [35] 1 F 77 right waist yes 8 ng/ml reddish papules n.a.
Masannat et al. (2007) [36] 1 M 63 left calf no 5 ng/ml like soft-tissue sarcoma n.a.
(AFP, alpha-fetoprotein; n.a.: not applicable).
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tions (see Tables 1 and 2).
We present a case of a 75-year-old man with singular
abdominal wall metastasis of differentiated, AFP-
negative hepatocellular carcinoma without a history of
prior seeding and without prior surgery to the abdom-
inal wall. This is the first report of a case with hepatocel-
lular carcinoma metastasis to the abdominal wall within
a pre-existing subcutaneous lipoma since childhood and
after antiandrogen therapy for prostate cancer since
2005.Table 2 Study with 21 patients with 24 non-iatrogenic
subcutaneous HCC metastases from 1 January 1998 to 31
December 2005 [53]
Head Chest Back Abdominal wall Arms and legs
Huang Y-J et al.
(2008) [53]
8 6 4 5 1
Long-term study on non-iatrogenic subcutaneous HCC metastases.This article provides a surgical approach, including ab-
dominal wall reconstruction, and a current review of the
literature as cited in PubMed.
Case presentation
Preoperative diagnostics and medical history
Our patient was referred to our center in March 2010
for diagnostic evaluation of a growing liver mass in liver
segment II (3.9 × 2.6 × 3.0 cm). He was in good general
condition with an obese nutritional status (Body Mass
Index 30.4 kg/m²) and an impression of fatty liver paren-
chyma in ultrasound and magnetic resonance imaging.
He was reported to drink two glasses of whisky per day.
The previous history included multiple subcutaneous lip-
omas within the abdominal wall since childhood and
prostate carcinoma, which was diagnosed in 2005 and
removed by prostatectomy (pT2, pN0, MO, G3) in the
same year, followed by antiandrogen therapy with leu-
prorelin and buserelin acetate until August 2008. The
multiple lipomas showed a marked progression in size
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August 2008. Final diagnostic evaluation, including
ultrasound-guided FNAB of the liver mass and magnetic
resonance imaging, resulted in the diagnosis of a multilo-
cular, well-differentiated and AFP-negative hepatocellular
carcinoma in liver segments II/III, VI, and VIII in April
2010. AFP levels stayed within normal range at all times
during further follow-up. Viral hepatitis or other risk fac-
tors for hepatocellular carcinoma like hemochromatosis,
liver fibrosis or liver cirrhosis could be ruled out. After
interdisciplinary tumor board consultation (including
surgeons, oncologists, radiologists, radio-oncologists and
hepatologists) transarterial chemoembolisation (TACE)
was performed from July 2010 to January 2011 every two
months leading to a complete remission.
Consultation with our surgical service was initiated in
November 2011 due to a hard palpable subcutaneous
mass with a diameter of approximately 7 cm that had
developed recently in the left upper abdominal wall,
exactly where a soft subcutaneous lipoma manifestation
has been, in the consciousness of the patient, since his
childhood (see Figures 1 and 2). The patient assured us
that FNAB had not been performed in the region of the
pre-existing multiple lipomas in the left upper abdominal
wall. This was consistent with the documentation of pre-
vious diagnostic work-up. Our patient was concerned
about the marked change in size and consistency of the
tumor in the left abdominal wall with concomitant dar-
kening of the skin directly adjacent to the tumor (see
Figure 2). Due to the patient’s medical history, the newly
occurred subcutaneous tumorous mass in the left ab-
dominal wall had to be suspected to be malignant. After
ultrasound evaluation of the subcutaneous mass, a re-
staging computed tomography was initiated that demon-
strated a tumor with a diameter of 7 cm within the left
upper abdominal wall with no signs of lymph node me-
tastasis, lung metastasis or any current hepatic tumorFigure 1 Computed tomography scan showing a tumor with a
diameter of 7 cm in the left upper abdominal wall.(see Figure 1). After interdisciplinary tumor board con-
sultation (including surgeons, oncologists, radiologists,
radio-oncologists and hepatologists) it was decided to
recommend tumor resection and abdominal wall
reconstruction.Surgical therapy
We removed the tumor by resection of the skin with
surrounding subcutaneous tissue en bloc with the sur-
rounding upper left rectus abdominis muscle including
the fascia. The resulting abdominal wall defect was too
large for primary closure or component separation. We
therefore decided to reconstruct the large defect in the
abdominal wall fascia with a synthetic, partially resorb-
able monocryl-prolene mesh that we inserted into the
defect of the fascia with a running monocryl-prolene su-
ture without opening the peritoneal cavity. Fortunately,
the peritoneum with the subfascial fat tissue layer could
be easily separated from the tumor without risking in-
complete resection. It was macroscopically evident that
the peritoneum was not infiltrated by the tumor. In
order to enable a tension-free primary wound and skin
closure, we covered the mesh with a local flap and in-
stalled two Redon drains (size 12 Charrière) subcutane-
ously with suction for a total of five days (see Figures 2,
3 and 4).Figure 2 Preoperative marking lines for the flap plastic.
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The clinical course after resection was uneventful. There
was primary wound healing without any signs of infec-
tion or hematoma. Thus, the inserted drains could be
removed after five days. Laboratory analysis evidenced
slightly elevated infectious parameters during the first
postoperative days, probably due to the surgical stimulus;
however, these declined and were within normal range
after hospital discharge. The mobilization was uneventful
as well as oral food intake and intestinal motility.
Final pathological workup showed a hepatocellular car-
cinoma with a trabecular and pseudoglandular growth
pattern (see Figure 5) with moderately atypical hepatocytes
(G2) and multifocal bile formation without steatosis (see
Figure 6). Immunohistochemistry was performed according
to standard procedures using monoclonal antibodies for
human androgen receptor (mouse clone AR441, Dako,
Hamburg, Germany) as well as estrogen and progesterone
receptor (rabbit SP1, and mouse PgR636, respectively,
Dako) and polyclonal for AFP (rabbit, Dako). Multiple tis-
sue blocks from different sites of the HCC showed no ex-
pression of the androgen receptor (see Figure 7).
Furthermore, there was no detectable expression of AFP, es-
trogen or progesterone receptor. By gross examination, a
subcutaneous lipomatous nodule of about 3 × 2 × 1.5 cmFigure 3 Shown is the resected abdominal wall metastasis. The
resection margins were macroscopically and microsopically tumor-
free.adjacent to the HCC could be identified. The histological
findings were well compatible with the diagnosis of a lip-
oma, the sex hormone receptor status of the adipocytes was
negative (Figures 8, 9).
Discussion
Abdominal wall metastasis of primary hepatocellular car-
cinoma is generally a comparatively rare entity (for a
summary of previously published cases, see Tables 1 and
2). Mostly described as the consequence of tumor seed-
ing after percutaneous interventions, the metastatic po-
tential of hepatocellular carcinoma without prior seeding
has so far not been described in detail. The pathophysio-
logical process of abdominal wall metastasis without
prior seeding is poorly understood. In cases with liver
cirrhosis, portal venous backflow mechanisms via collat-
erals in the abdominal wall may play a hypothetic role
for the development of abdominal wall metastasis. Our
patient had no cirrhosis and no significant portal venous
collaterals in the abdominal wall.
Our patient underwent a previous prolonged period of
antiandrogen therapy with leuprorelin and buserelin
acetate with the intention to treat his prostate carcinoma
until August 2008. It well may be that this treatment signifi-
cantly contributed to the fact that our patient developed a
differentiated, AFP-negative abdominal wall metastasisFigure 4 Abdominal wall six days after tumor resection with
subcutaneous flap plastic and staple sutures.
Figure 5 Hepatocellular carcinoma with trabecular and
pseudoglandular growth pattern (H&E stain, original
magnification 20x).
Figure 7 Immunohistochemical staining for androgen receptor
negative in the tumor cell nuclei (original magnification 200x).
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the histomorphologically mature phenotype of the HCC
metastasis, the neoplastic hepatocytes showing no steatosis
and no expression of the androgen receptor.
It is interesting to note that the abdominal wall lipoma
demonstrated an accelerated growth during antiandro-
gen therapy. This may have contributed to haematogen-
ous spread of HCC to the abdominal wall. Interestingly,
numerous lines of evidence point to a role of androgens
in the development of hepatocellular carcinoma [37-42].
It could be demonstrated that the majority of hepato-
cellular carcinoma cells express androgen receptors in
higher levels as compared to normal hepatocytes [37-42].
Taken together epidemiologic, clinical, biologic and ex-
perimental studies have provided a strong rationale for
antiandrogen therapy in hepatocellular carcinomaFigure 6 Hepatocellular carcinoma with moderately atypical
hepatocytes with multifocal bile formation (H&E stain, original
magnification 200x).(HCC). Epidemiological studies demonstrated that the
sex ratio for HCC arising in cirrhotic patients is eleven
men for one woman, whereas the sex ratio in cirrhotic
patients without HCC is less than two men for one
woman [43]. Animal studies demonstrated that carcino-
gens induce HCC more easily in males than females.
Matsumoto et al. could demonstrate that transforming
growth factor alpha (TGF-alpha)-related hepatocarcino-
genesis and hepatocyte proliferation are increased by an-
drogenic stimulation in TGF-alpha transgenic mice [44].
Several clinical studies have reported occurrence of HCC
after administration of androgen therapy (for example,
with testosterone) in male subjects who suffer from
aplastic anemia or infertility [45-47]. Interestingly, stop-
ping androgen therapy usually led to regression of the
tumor [38].Figure 8 Immunohistochemical staining for estrogen receptor:
negative in the HCC (left) and lipomatous tissue (right) (original
magnification 40x).
Figure 9 Detail from the lipoma: mature adipocytes with no
atypia and a delicate fibrous tumor capsule (right, H&E stain)
(original magnification 100x).
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in 74 % of males and 37 % of females, and their presence
is associated with a more rapid progression of disease
[40]. Arguments against our speculation that previous
antiandrogen therapy may have caused the abdominal
wall metastasis in our patient to be differentiated and
AFP-negative may be derived from more recent data and
the fact that immunhistochemical staining was negative
in the tumor cell nuclei of our patient (see Figure 7).
Antiandrogens (for example. leuprorelin) have been used
in prospective randomized multicenter trials to treat
hepatocellular carcinoma [38,39]. One study with leu-
prorelin and flutamide demonstrated no benefit in sur-
vival for male patients with HCC treated with
antiandrogens [39]. Another study showed a lack of effi-
cacy of androgen treatment in unresectable HCC [38].
More recent studies with Cre-Lox conditional knock-
out mice model who lack androgen receptor (AR) ex-
pression demonstrated that the androgen receptor, but
not androgens, may be a potential new and better thera-
peutic target for the treatment of HCC [48]. A new ani-
mal study found that hepatic androgen receptor
promotes hepatitis B virus (HBV)-induced hepatocarci-
nogenesis in HBV transgenic mice that lack AR only in
the liver hepatocytes (HBV-L-AR(−/y). HBV-L-AR(−/y)
mice that received a low dose of the carcinogen N'-N'-
diethylnitrosamine have a lower incidence of HCC and
present with smaller tumor sizes, fewer foci formations,
and less alpha-fetoprotein HCC marker than do their
wild-type HBV-AR(+/y) littermates [49]. Taken together
it appears that the androgen receptor in HCC may be
more relevant for the biology of the tumor than the
androgens or antiandrogen treatment.
Due to the low incidence of subcutaneous abdominal
wall metastasis of HCC, therapeutic algorithms arewidely missing. In the current literature, surgical resection
is the favored therapeutic option [13,23,32]. However, sur-
gical resection might be challenging depending on tumor
size, invasiveness and localization. Immediate definitive
closure of the wound is the preferred method. In cases
with distinct wound distension, local inflammation or
wound infect, temporary abdominal wall closure should be
considered [50]. Meanwhile, abdominal wall reconstruc-
tion is necessary due to the resulting abdominal wall de-
fect. Described methods include prosthetics or autologous
reconstruction such as abdominal components separation
or local flaps. Generally, deeper and larger wound defects
that include the myofascia may require a synthetic, par-
tially resorbable monocryl-prolene mesh to replace the
resected myofascia that may have to be covered by a free
tissue or a distant flap in order to reduce wound tension
[51]. The local flap used in this case to cover the implanted
partially resorbable monocryl-prolene mesh for abdominal
wall reconstruction is a well-established procedure and
proved successful during follow-up in this case [52]. In
our opinion, resection of hepatocellular carcinoma metas-
tases to the abdominal wall with peritoneal infiltration
may require a modified approach for abdominal wall re-
construction, for example, with the use of a dual-layer
mesh that is able to reduce postoperative adhesions be-
tween the intestine and the mesh within the intraperito-
neal cavity. Fortunately in this case, opening of the
peritoneal cavity could be avoided.
Huan et al. reported 21 patients with a subcutaneous
HCC metastasis without seeding who were treated by
radiotherapy (see Table 2) [53].
Single cases are not discussed in detail, so comparison
with our work or the reports of other cases is barely pos-
sible. There is a substantial lack of evidence for adjuvant
chemotherapeutic approaches after potentially curative
resection of abdominal wall metastasis. In order to estab-
lish therapeutic algorithms for cutaneous metastasis of
hepatocellular carcinoma, the initiation of large multi-
center studies would be desirable in order to be able to
create scientific evidence [54,55]. Due to the rarity of cu-
taneous metastasis of hepatocellular carcinoma, this is a
major and potentially unsolvable challenge.
Conclusions
We believe that in our case the abdominal wall metasta-
sis is a consequence of systemic arterial tumor spread to
a pre-existing lipoma since childhood via its blood sup-
ply. To our knowledge, this is the first report of such a
case. Our case highlights that suspicion of abdominal
wall metastasis of hepatocellular carcinoma is also justi-
fied in patients with pre-existing, long-standing palpable
abdominal lipoma since childhood, especially when ap-
parent growth of these nodules is being observed. We
recommend surgical removal and abdominal wall
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avoid tumor necrosis at the abdominal wall and/or infil-
tration of the small or large bowel followed by potential
percutaneous bowel perforation. Cases with a singular
hepatocellular metastasis to the abdominal wall with
otherwise complete surgical resection of the primary
tumor may benefit from resection with potential im-
provement of survival.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
AFP: alpha-feto protein; AR: androgen receptor; FNAB: fine needle aspiration
biopsy; H&E: hematoxylin and eosin; HBV: hepatitis B virus;
HCC: hepatocellular carcinoma; n.a: not applicable; PEI: percutaneous ethanol
injection; TACE: transarterial chemoembolisation; TGF-alpha: transforming
growth factor alpha.
Competing interests
The authors declare they have no competing interests. The authors have no
conflict of interest to disclose which may have biased their work. The authors
declare that they did not receive any funding for this work.
Acknowledgements
The authors would like to acknowledge DFG sponsorship for the publication
costs of open access publication.
Author details
1General, Visceral und Transplantation Surgery, Hanover Medical School,
Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 2Trauma Department,
Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
3Institute of Pathology, Hanover Medical School, Carl-Neuberg-Str. 1, 30625
Hannover, Germany. 4Department of Gastroenterology, Hepatology and
Endocrinology, Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover,
Germany.
Authors’ contributions
LZ operated on the patient, collected the majority of relevant clinical data
and drafted the manuscript. CZ was involved in the collection of data and
helped significantly with the writing of the manuscript. SJ carried out the
histological examination of the resected specimen, including
immunohistochemistry, and helped with the writing of the manuscript. JTS
researched the literature for this case and contributed significantly with
tables and relevant intellectual comments on the manuscript. CMH helped
significantly with the writing of the manuscript and contributed an
important interdisciplinary viewpoint that helped substantially improve the
intellectual content of the manuscript. MW participated in the design of the
report and helped to improve the intellectual content of the manuscript. JK
provided relevant surgical experience and advice and helped to improve the
intellectual content of the manuscript. HS had the idea to write this case
report, participated significantly in its design and coordination and helped to
improve the intellectual content of the manuscript. All authors read and
approved the final manuscript.
Authors’ information
All authors of this article are clinically highly experienced physicians who
are regularly involved with interdisciplinary treatment decisions for patients
with hepatocellular carcinoma (HCC), encompassing up-to-date
interventional, chemotherapeutic, and surgical approaches, including liver
resection and liver transplantation, in one of the largest academic treatment
centres for HCC in Germany.Received: 3 February 2012 Accepted: 30 May 2012
Published: 30 May 2012References
1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and
molecularcarcinogenesis. Gastroenterology 2007, 132:2557–2576.
2. Deuffic S, Poynard T, Buffat L, Valleron AJ: Trends in primary liver cancer.
Lancet 1998, 351:214–215.
3. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M,
Galante D, Manghisi OG, Mazzanti R, Medaglia C, Pilleri G, Rapaccini GL,
Simonetti RG, Taliani G, Tosti ME, Villa E, Gasbarrini G: Characteristics of
hepatocellular carcinoma in Italy. J Hepatol 1998, 29:944–952.
4. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC: Increase
in primary liver cancer in the UK, 1979–94. Lancet 1997, 350:1142–1143.
5. Bosch FX, Ribes J, Díaz M, Cléries R: Primary liver cancer: worldwide
incidence and trends. Gastroenterology 2004, 127(5 Suppl 1):S5–S16.
6. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y,
Toyota J, Suga T, Asaka M: Clinical features of hepatocellular carcinoma
with extrahepatic metastases. J Gastroenterol Hepatol 2005, 20:1781–1787.
7. Katyal S, Oliver JH 3RD, Peterson MS, Ferris JV, Carr BS, Baron RL:
Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000,
216:698–703.
8. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, Ikari T:
Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases
autopsied in ten years. Cancer 1983, 51:863–877.
9. Okuda K, Konda Y: Primary carcinoma of the liver. In Bockus
gastroenterology. 5th edition. Edited by Haubrich WS, Schaffner F, Berk JE.
Philadelphia: WB Saunders; 1995:2444–2489.
10. MacDonald RA: Primary carcinoma of the liver: a clinicopathological study
of 108 cases. Arch Intern Med 1967, 99:266–79.
11. Jegou J, Perruzi P, Arav E, Pluot M, Jaussaud R, Remy G: Cutaneous and
bone metastases revealing hepatocarcinoma. Gastroenterol Clin Biol 2004,
28:804–806.
12. de Agustín P, Conde E, Alberti N, Pérez-Barrios A, López-Ríos F: Cutaneous
metastasis of occult hepatocellular carcinoma: a case report. Acta Cytol
2007, 51:214–216.
13. Hsieh CT, Sun JM, Tsai WC, Tsai TH, Chiang YH, Liu MY: Skull metastasis
from hepatocellular carcinoma. Acta Neurochir (Wien). 2007, 149:185–190.
14. Royer MC, Rush WL, Lupton GP: Hepatocellular carcinoma presenting as a
precocious cutaneous metastasis. Am J Dermatopathol 2008, 30:77–80.
15. Magana M, Gomez LM: Skin metastasis from hepatocarcinoma. Am J
Dermatopathol 2009, 31:502–505.
16. Lazaro M, Allende I, Ratón JA, Acebo E, Diaz-Perez JL: Cutaneous
metastases of hepatocellular carcinoma. Clin Exp Dermatol 2009, 34:e567–
569.
17. Fukushima M, Katagiri A, Mori T, Watanabe T, Katayama Y: Case of skull
metastasis from hepatocellular carcinoma at the site of skull fracture. No
Shinkei Geka 2010, 38:371–377.
18. Lee GK, Lorenz HP, Mohan SV: A rare case of mistaken identity: metastatic
hepatocellular carcinoma to the nose. JSCR. 2010, 4:3.
19. Isa NM, Bong JJ, Ghani FA, Rose IM, Husain S, Azrif M: “Cutaneous
metastasis of hepatocellular carcinoma diagnosed by fine needle
aspiration cytology and Hep Par 1 immunopositivity“. Diagn
Cytopathology 2011. doi:10.1002/dc.21706.
20. Ackerman D, Barr RJ, Elias AN: Cutaneous metastases from hepatocellular
carcinoma. Int J Dermatol 2001, 40:782–784.
21. Braune C, Widjaja A, Bartels M, Bleck JS, Flemming P, Manns MP,
Klempnauer J, Gebel M: Surgical removal of a distinct subcutaneous
metastasis of multilocular hepatocellular carcinoma 2 months after initial
percutaneous ethanol injection therapy. Z Gastroenterol 2001, 39:789–792.
22. Al-Mashat FM: Hepatocellular carcinoma with cutaneous metastasis. Saudi
Med J 2004, 25:370–372.
23. Amador A, Monforte NG, Bejarano N, Martí J, Artigau E, Navarro S, Fuster J:
Cutaneous metastasis from hepatocellular carcinoma as the first clinical
sign. J Hepatobiliary Pancreat Surg 2007, 14:328–330.
24. Terada T, Sugiura M: “Metastatic hepatocellular carcinoma of skin
diagnosed with hepatocyte paraffin 1 and a-fetoprotein
immunostainings“. Int J Surg Pathol 2010, 18:433–436.
25. Suzuki H, Kuwano H, Masuda N, Hashimoto S, Saitoh T, Kanoh K, Nomoto K,
Shimura T: Resected case of a double cancer, a hepatocellular carcinoma
Zachau et al. World Journal of Surgical Oncology 2012, 10:98 Page 8 of 8
http://www.wjso.com/content/10/1/98and cholangiocellular carcinoma, and their spread to the skin.
Hepatogastroenterology 2003, 50:362–365.
26. Lee MC, Huang YL, Yang CH, Kuo TT, Hong HS: Cutaneous seeding of
hepatocellular carcinoma due to percutaneous ethanol injection and
masquerading as a pyogenic granuloma. Dermatol Surg 2004, 30:438.
27. Hyun YS, Choi HS, Bae JH, Jun DW, Lee HL, Lee OY, Yoon BC, Lee MH, Lee
DH, Kee CS, Kang JH, Park MH: Chest wall metastasis from unknown
primary site of hepatocellular carcinoma. World J Gastroenterol 2006,
12:2139–2142.
28. Nggada HA, Ajayi NA: “Cutaneous metastasis from hepatocellular
carcinoma: a rare presentation and review of the literature“. Afr J Med
Med Sci 2006, 35(2):181–182. review.
29. Martínez Ramos D, Villegas Cánovas C, Senent Vizcaíno V, et al:
“Subcutaneous seeding of hepatocellular carcinoma after fine-needle
percutaneous biopsy“. Rev Esp Enferm Dig 2007, 99(6):354–357. Spanish.
30. Rowe LR, Mulvihill SJ, Emerson L, Gopez EV: Subcutaneous tumor seeding
following needle core biopsy of hepatocellular carcinoma. Diagn
Cytopathol 2007, 35:717–721.
31. Özdil B, Akkiz H, Sandikci M, et al: Giant subcutaneous HCC case occurring
after percutaneous ethanol injection. Turk J Gastroenterol 2009, 20:301–
302.
32. Chen YY, Yen HH: Subcutaneous metastases after laparoscopic-assisted
partial hepatectomy for hepatocellular carcinoma. Surg Laparosc Endosc
Percutan Tech 2011, 21:e41–43.
33. Fang YR, Huang YS, Wu JC, Chao Y, Tsay SH, Chan CY, Chang FY, Lee SD: An
unusual cutaneous metastasis from hepatocellular carcinoma. Zhonghua
Yi Xue Za Zhi 2001, 64:253–257.
34. Kanitakis J, Causeret AS, Claudy A, Scoazec JY: Cutaneous metastasis of
hepatocellular carcinoma diagnosed with hepatocyte paraffin (Hep Par
1) antibody immunohistochemistry. J Cutan Pathol 2003, 30:637–640.
35. Nagaoka Y, Nakayama R, Iwata M: Cutaneous seeding following
percutaneous ethanol injection therapy for hepatocellular carcinoma.
Intern Med. 2004, 43:268–269.
36. Masannat YA, Achuthan R, Munot K, Merchant W, Meaney J, McMahon MJ,
Horgan KJ: Solitary subcutaneous metastatic deposit from hepatocellular
carcinoma. N Z Med J 2007, 120:U2837.
37. Zhang J, Huang G, Huang W: Gonadotropin releasing hormone and its
receptor in the tissue of human hepatocellular carcinoma. Zhonghua Yi
Xue Za Zhi 1998, 78:343–346.
38. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L,
Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils
J: Evaluation of antiandrogen therapy in unresectable hepatocellular
carcinoma: results of a European Organization for Research and
Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998,
16:411–417.
39. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire:
Randomized trial of leuprorelin and flutamide in male patients with
hepatocellular carcinoma treated with tamoxifen. Hepatology 2004,
40:1361–1369.
40. Nagasue N, Chang YC, Hayashi T, Galizia G, Kohno H, Nakamura T, Yukaya H:
Androgen receptor in hepatocellular carcinoma as a prognostic factor
after hepatic resection. Ann Surg 1989, 209:424–427.
41. Nagasue N, Galizia G, Yukaya H, Kohno H, Chang YC, Hayashi T, Nakamura T:
Better survival in women than in men after radical resection of
hepatocellular carcinoma. Hepatogastroenterology 1989, 36:379–383.
42. Negro F, Papotti M, Pacchioni D, Galimi F, Bonino F, Bussolati G: Detection
of human androgen receptor mRNA in hepatocellular carcinoma by in
situ hybridisation. Liver 1994, 14:213–219.
43. Johnson PJ, Krasner N, Portmann B, Eddleston AL, Williams R: Hepatocellular
carcinoma in Great Britain: influence of age, sex, HBsAg status, and
aetiology of underlying cirrhosis. Gut 1978, 19:1022–1026.
44. Matsumoto T, Takagi H, Mori M: Androgen dependency of
hepatocarcinogenesis in TGFalpha transgenic mice. Liver 2000, 20:228–33.
A published erratum appears in Liver 2004, 24:275.
45. Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, Kronenberg H:
Androgen-induced hepatoma. Lancet 1975, 1:430–432.
46. Guy JT, Auslander MO: Androgenic steroids and hepatocellular carcinoma.
Lancet 1973, 1:148.
47. Goldfarb S: Sex hormones and hepatic neoplasia. Cancer Res 1976,
36:2584–2588.48. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S,
Chang C: Androgen receptor is a new potential therapeutic target for the
treatment of hepatocellular carcinoma. Gastroenterology 2008, 135:947–
955.
49. Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang
C: Androgen receptor promotes hepatitis B virus-induced
hepatocarcinogenesis through modulation of hepatitis B virus RNA
transcription. Sci Transl Med 2010, 2:32ra35.
50. Rohrich RJ, Lowe JB, Hackney FL, Bowman JL, Hobar PC: Plast Reconstr
Surg. An algorithm for abdominal wall reconstruction. Plast Reconstr Surg
2000, 105:202–216.
51. Rudolph R, Klein L: Healing process in skin grafts. Surg Gynecol Obstet 1973,
136:641–654.
52. Buck DW 2nd, Khalifeh M, Redett RJ: Plastic surgery repair of abdominal
wall and pelvic floor defects. Urol Oncol 2007, 25:160–164.
53. Huang YJ, Tung WC, Hsu HC, Wang CY, Huang EY, Fang FM: Radiation
therapy to non-iatrogenic subcutaneous metastasis in hepatocellular
carcinoma: results of a case series. Br J Radiol 2008, 81:143–150.
54. : Levels of Evidence. Oxford Centre for Evidence-based Medicine 2009, http://
www.cebm.net/index.aspx?o=1025. 2010.
55. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz
J: Hepatocellular carcinoma: current management and perspectives for
the future. Ann Surg 2011, 253:453–469.
doi:10.1186/1477-7819-10-98
Cite this article as: Zachau et al.: Haematogenous abdominal wall
metastasis of differentiated, alpha-fetoprotein-negative hepatocellular
carcinoma after previous antiandrogen therapy within a site of lipoma
manifestation since childhood. World Journal of Surgical Oncology 2012
10:98.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
